Aller au contenu principal
2026 article

Antigen-Loaded and Calcium-Incorporated Chitosan Oligosaccharide Nanoparticles for Dendritic Cell Cross-Presentation and Immunotherapy

0Citations signalées, ce qui n’est pas une note de qualité
0Institutions déclarées
0Pays d’affiliation déclarés

Le résumé fourni par la source

Cheng-Ping Yu, Jui-Chen Tsai, Yan-Jye ShyongSchool of Pharmacy, College of Medicine, National Cheng Kung University, Tainan, TaiwanCorrespondence: Yan-Jye Shyong, Email bear901704@gs.ncku.edu.twBackground: Cancer vaccines, a type of immunotherapy for cancer treatment, have been extensively studied over the years. Antigen-presenting cells (APCs) such as dendritic cells (DCs) and macrophages play a crucial role in vaccine therapies by presenting specific antigens to helper or cytotoxic T cells. Nanoparticles, which can extend the half-life of antigens and offer targeted delivery, are ideal vaccine delivery systems.Methods: In this study, we utilized calcium-incorporated chitosan oligosaccharide nanoparticles (Ca-CS NPs) as carriers to load ovalbumin (OVA) and deliver it to DCs. We characterized the NPs, examined the cell uptake, cross-presentation and immune responses by cell in vitro. In vivo, the biodistribution, immune response, anti-tumor effects and safety of NPs were examined.Results: Both CS-OVA NPs and Ca-CS-OVA NPs remained stable at 4 °C for 7 days and exhibited no cytotoxicity toward DC2.4 and RAW 264.7 cells. Compared with OVA and CS-OVA NPs, Ca-CS-OVA NPs effectively promoted the maturation of bone marrow-derived dendritic cells (BMDCs) and induced stronger Th1 response in vitro. In vivo studies demonstrated that Ca-CS-OVA was distributed into lymph nodes and enhanced immune responses following subcutaneous administration. Moreover, Ca-CS-OVA NPs in combination with aCTLA-4 showed the best anti-tumor efficacy without adverse events.Conclusion: These findings indicate that Ca-CS NPs possess good biocompatibility and are a potential platform for cancer vaccine-based immunotherapies.Keywords: chitosan oligosaccharide, calcium ion, dendritic cell, cancer vaccine, immunotherapy

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

Aucun DOI disponible pour le contrôle Crossref.

Les sujets associés

Immunotherapy and Immune ResponsesRNA Interference and Gene DeliveryAdvanced Drug Delivery Systems

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.